Trial Profile
A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer; Brain metastases
- Focus Registrational; Therapeutic Use
- Acronyms CEREBREL
- Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals
- 18 May 2018 Status changed from active, no longer recruiting to completed.
- 03 May 2018 This trial has been completed in Hungary (end date: 2018-03-22)
- 25 Apr 2018 This trial has been completed in Sweden (end date: 2018-03-22)